Centene has sold off Magellan Rx to Prime Therapeutics for $1.5 billion, a move that will add Magellan’s specialty drug management to Prime’s pharmacy benefit management tools.
The end result, the companies said, will be a “diversified pharmacy solutions organization” serving commercial markets and government programs.
